Bill Cook joins BioPlus as VP sales
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has named Bill Cook VP sales, the company said.
Cook previously worked as SVP business development and sales at CareSouth and also has worked as VP sales at United Therapeutics, Accredo Health and Gentiva. In his new position with BioPlus, Cook will be responsible for the national sales force.
“Bill brings over 23 years of healthcare industry experience as a dynamic, high-performance sales executive to his new position at BioPlus,” BioPlus president and CEO Stephen Vogt said. “His extensive experience in building and leading top-flight sales teams, strategic planning, incentive compensation design and market positioning is the perfect match for BioPlus as our company continues to grow and expand in the specialty pharmacy industry.”
Novo Nordisk, Children with Diabetes team up to educate newly diagnosed Type 1 diabetics
ORLANDO, Fla. — Danish drug maker Novo Nordisk will work with advocacy group Children with Diabetes to distribute materials to children newly diagnosed with Type 1 diabetes, the two said Thursday.
The approximately 7,000 kits, designed to help them learn to live with the condition, include a booklet, savings offers and patient-support videos, and were created based on feedback from CWD members with Type 1 diabetes. Patients can order the kits through their doctors.
Approximately 15,600 children and adolescents in the United States are diagnosed with Type 1 diabetes every year, according to Novo Nordisk and CWD.
Watson seeks FDA approval for generic Vyvanse
PARSIPPANY, N.J. — Watson Pharmaceuticals has filed with the Food and Drug Administration for regulatory approval for a drug to treat attention deficit hyperactivity disorder, the company said Thursday.
Watson said it submitted its application for lisdexamfetamine dimesylate capsules, a generic version of Shire’s Vyvanse.
Shire has filed a patent infringement suit against Watson in the U.S. District Court for the Central District of California in an attempt to prevent Watson from marketing its version of the drug. Under laws governing generic drugs, the FDA can’t approve Watson’s generic version of Vyvanse until August 2014 or until the companies resolve the matter before the court.